Pharmacokinetics and hematotoxicity of a novel copper-based anticancer agent: Casiopeina III-Ea, after a single intravenous dose in rats

Fundamental and Clinical Pharmacology

Volumn 28, Issue 1, 2014, Pages 78-87

  Vértiz, Guadalupe ^a   García Ortuño, Luis Enrique ^a   Bernal, Juan Pablo ^b   Bravo Gómez, María Elena ^a   Lounejeva, Elena ^c   Huerta, Amada ^a   Ruiz Azuara, Lena ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b CENTRO DE GEOCIENCIAS   (Mexico)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Casiopeinas; Copper; Hematotoxicity; Mixed chelate; Pharmacokinetics

Indexed keywords

ALANINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BILIRUBIN; CASIOPEINA III EA; CHLORIDE; COPPER COMPLEX; CREATININE; FIBRINOGEN; HEMOGLOBIN; IRON; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; UREA; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; COMPARTMENT MODEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EOSINOPHIL; ERYTHROCYTE; HEMATOCRIT; HEMOLYSIS; IRON BLOOD LEVEL; LETHAL DOSE; LEUKOCYTE; LYMPHOCYTE; MALE; MASS SPECTROMETRY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MEAN RESIDENCE TIME; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; STUDY DESIGN; THROMBOCYTE COUNT; URINALYSIS; ZINC BLOOD LEVEL;

CASIOPEINAS; COPPER; HEMATOTOXICITY; MIXED CHELATE; PHARMACOKINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; COPPER; ERYTHROCYTES; INJECTIONS, INTRAVENOUS; IRON; MALE; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR; ZINC;

EID: 84892544826     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01075.x     Document Type: Article

References (43)

1. Shah N., Dizon D.S. New-generation platinum agents for solid tumors. Future Oncol. (2009) 5 33-42.
2. Cossa G., Gatti L., Zunino F., Perego P. Strategies to improve the efficacy of platinum compounds. Curr. Med. Chem. (2009) 16 2355-2365.
3. Ruiz-Azuara L., Bravo-Gómez M.E. Copper compounds in cancer chemotherapy. Curr. Med. Chem. (2010) 17 3606-3615.
4. Huang R., Wallqvist A., Covell D.G. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem. Pharmacol. (2005) 69 1009-1039.
5. Ruiz-Azuara L. United States Patent 1992, vol. RE 35, 458, February 18, 1997.
6. Ruiz-Azuara L. United States Patent 1996, vol. 5, 576, 326.
7. 3 complexes, (Casiopeínas). J. Inorg. Biochem. (2009) 103 299-309.
8. Alemón-Medina R., Breña-Valle M., Muñoz-Sánchez J.L., Gracia-Mora M.I., Ruiz-Azuara L. Induction of oxidative damage by copper-based antineoplastic drugs (Casiopeínas). Cancer Chemother. Pharmacol. (2007) 60 219-228.
9. Serment-Guerrero J., Cano-Sanchez P., Reyes-Perez E., Velazquez-Garcia F., Bravo-Gomez M.E., Ruiz-Azuara L. Genotoxicity of the copper antineoplastic coordination complexes casiopeinas. Toxicol. In Vitro (2011) 25 1376-1384.
10. Trejo-Solís C., Palencia G., Zúñiga S., Rodríguez-Ropon A., Osorio-Rico L., Luvia S.T., et al. Cas IIgly induces apoptosis in glioma C6 cells in vitro and in vivo through caspase-dependent and caspase-independent mechanisms. Neoplasia. (2005) 7 563-574.
11. Carvallo-Chaigneau F., Trejo-Solís C., Gómez-Ruiz C., Rodríguez-Aguilera E., Macías-Rosales L., Cortés-Barberena E., et al. Casiopeina III-ia induces apoptosis in HCT-15 cells in vitro through caspase-dependent mechanisms and has antitumor effect in vivo. Biometals (2008) 21 17-28.
12. De Vizcaya-Ruiz A., Rivero-Muller A., Ruiz-Ramirez L., Kass G.E., Kelland L.R., Orr R.M., et al. Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells. Toxicol. In Vitro (2000) 14 1-5.
13. Marín-Hernández A., Gracia-Mora I., Ruiz-Ramírez L., Moreno-Sánchez R. Toxic effects of copper-based antineoplastic drugs (Casiopeinas) on mitochondrial functions. Biochem. Pharmacol. (2003) 65 1979-1989.
14. Hernández-Esquivel L., Marín-Hernández A., Pavón N., Carvajal K., Moreno-Sánchez R. Cardiotoxicity of copper-based antineoplastic drugs casiopeinas is related to inhibition of energy metabolism. Toxicol. Appl. Pharmacol. (2006) 212 79-88.
15. Kachadourian R., Brechbuhl H.M., Ruiz-Azuara L., Gracia-Mora I., Day B.J. Casiopeína IIgly-induced oxidative stress and mitochondrial dysfunction in human lung cancer A549 and H157 cells. Toxicology (2010) 268 176-183.
16. De Vizcaya-Ruiz A., Rivero-Müller A., Ruiz-Ramirez L., Howarth J.A., Dobrota M. Hematotoxicity response in rats by the novel copper-based anticancer agent: casiopeina II. Toxicology (2003) 194 103-113.
17. Duffull S.B., Robinson B.A. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin. Pharmacokinet. (1997) 33 161-183.
18. Hopfer S.M., Ziebka L., Sunderman F.W. Jr, Sporn J.R., Greenberg B.R. Direct analysis of platinum in plasma and urine by electrothermal atomic absorption spectrophotometry. Ann. Clin. Lab. Sci. (1989) 19 389-396.
19. De Waal W.A., Maessen F.J., Kraak J.C. Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media. J. Pharm. Biomed. Anal. (1990) 8 1-30.
20. Ekborn A., Hansson J., Ehrsson H. et al. High-dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. (2004) 114 1660-1667.
21. Vermorken J.B., van der Vijgh W.J., Klein I. et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther. (1986) 39 136-144.
22. Urien S., Brain E., Bugat R., Pivot X., Lochon I., Van M.L., et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother. Pharmacol. (2005) 55 55-60.
23. Lee H.B., Blaufox M.D. Blood volume in the rat. J. Nucl. Med. (1985) 26 72-76.
24. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. (2002) 91 129-156.
25. Shargel L., Wu-Pong S., Yu A. Applied biopharmaceutics and pharmacokinetics, 5th edn. McGraw-Hill Medical, USA, 2004.
26. Kim B.E., Nevitt T., Thiele D.J. Mechanisms for copper acquisition, distribution and regulation. Nat. Chem. Biol. (2008) 4 176-185.
27. Cai X., Pan N., Zou G. Copper-1, 10-phenanthroline-induced apoptosis in liver carcinoma Bel-7402 cells associates with copper overload, reactive oxygen species production, glutathione depletion and oxidative DNA damage. Biometals (2007) 20 1-11.
28. Rifkind J.M. Copper and the autoxidation of hemoglobin. Biochemistry (1974) 13 2475-2481.
29. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin. Pharmacokinet. (2003) 42 779-791.
30. Dumez H., Guetens G., De Boeck G., Highley M.S., Maes R.A., van Oosterom A.T., et al. The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment. Clin. Chem. Lab. Med. (2004) 42 1219-1227.
31. Lévi F., Metzger G., Massari C., Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. (2000) 38 1-21.
32. Irato P., Albergoni V. Interaction between copper and zinc in metal accumulation in rats with particular reference to the synthesis of induced-metallothionein. Chem. Biol. Interact. (2005) 155 155-164.
33. Bremner I. Manifestations of copper excess. Am. J. Clin. Nutr. (1998) 67 1069S-1073S.
34. MacKellar W.C., Crane F.L. Iron and copper in plasma membranes. J. Bioenerg. Biomembr. (1982) 14 241-247.
35. Shinar E., Rachmilewitz E.A., Shifter A., Rahamim E., Saltman P. Oxidative damage to human red cells induced by copper and iron complexes in the presence of ascorbate. Biochim. Biophys. Acta (1989) 1014 66-72.
36. Konukoglu D., Ercan M., Ayaz M., Onen S. Plasma and erythrocytes antioxidant status and trace element levels in proteinuric patients with moderate glomerular function. J. Trace Elem. Med Biol. (2001) 15 119-122.
37. Labieniec M., Milowska K., Balcerczyk A., Rucinska A., Sadowska M., Jokiel M., et al. Interactions of free copper (II) ions alone or in complex with iron (III) ions with erythrocytes of marine fish Dicentrarchus labrax. Cell Biol. Int. (2009) 33 941-948.
38. Theil E.C., Calvert K.T. The effect of copper excess on iron metabolism in sheep. Biochem. J. (1978) 170 137-143.
39. Sansinanea A.S., Cerone S.I., Elperding A., Auza N. Glucose-6-phosphate dehydrogenase activity in erythrocytes from chronically copper-poisoned sheep. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol. (1996) 114 197-200.
40. Cooper G.L., Bickford A.A., Charlton B.R., Galey F.D., Willoughby D.H., Grobner M.A. Copper poisoning in rabbits associated with acute intravascular hemolysis. J. Vet. Diagn. Invest. (1996) 8 394-396.
41. Rolfe D.S., Twedt D.C. Copper-associated hepatopathies in dogs. Vet. Clin. North. Am Small Anim. Pract. (1995) 25 399-417.
42. Giuliodori M.J., Ramírez C.E., Ayala M. Acute copper intoxication after a Cu-Ca EDTA injection in rats. Toxicology (1997) 124 173-177.
43. Stockham S.L., Scott M.A. Fundamentals of veterinary clinical pathology, 2nd edn. Wiley-Blackwell, IA, USA, 2008.